Abstract: The invention relates to a process for the treatment of animal skim milk and for the production of an infant formula base product from animal skim milk, which process is highly efficient and cost effective, as only membrane filtration techniques, such as microfiltration and ultrafiltration, are required. By carefully controlling the process parameters, a product is obtained in which most of the major components are within the desired range for an infant formula base product. The invention also relates to products obtainable by the process according to the invention.

Abstract: The invention concerns a method for stimulating barrier integrity in a mammal by administering to a mammal a composition comprising: eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid (ARA), and at least two distinct oligosaccharides.

Abstract: The invention relates to improved liver health and lipid metabolism later in life upon ingestion of synbiotics early in life.

Abstract: The invention relates to improved liver health and lipid metabolism later in life upon ingestion of synbiotics early in life.

Abstract: The invention provides a system (100a) for tracking infant development, the system comprising: —a portable device (101) including a camera and a processing unit, and —a weighing scale (102), preferably comprising a wireless transceiver; wherein the weighing scale is configured to measure the weight of an infant and to transmit the measured weight information to the portable device; and wherein the portable device is configured to —capture (401) an image of the infant; —combine the received weight information and information derived from the image of the infant to obtain (404) infant development statistics; and —store (403) the image and the obtained infant development statistics in a storage; wherein the information derived from the image includes at least one of the height of the infant and the head circumference of the infant. The invention further provides a portable device, a weighing scale, and a computer readable medium.

Abstract: Nutritional compositions with fucosyllactose and betagalactooligosaccharides for use in stimulation of the immune system. The composition is suitable for infants.

Abstract: An infant formula for preventing gastro-esophageal reflux is disclosed comprising whey protein and/or casein, a galactomannan thickener, and a fermented milk-derived product.

Abstract: The invention thus pertains to the use of a composition comprising: (a) uridine or uridine phosphate; and (b) docosahexaenoic acid and/or eicosapentaenoic acid, for improving memory and/or the treatment or prevention of impaired memory function, in a subject with a mini-mental state examination of 24-26, wherein said composition is enterally administered to the subject. In the MISE test, any score of 27 or higher (out of 30) is effectively normal. In the patients with dementia, 20-26 indicates mild dementia, 10-19 moderate dementia, and below 10 severe dementia. It was the present inventors' belief that within the group of 20-26, the memory impairment in the sub-group of 24-26 may even be reversible, as the pathological pathways have just started to develop. In this group of subjects the pathological pathways have just started to develop. Clinical studies show excellent results for this subgroup.

Abstract: Claimed is the preparation of an infant formula base product, comprising: (a) microfiltration (ME) of animal skim milk over a membrane having a porosity of 0.10-0.35 micrometer and operating with a volume concentration factor of 1.5-8, resulting in a retentate (MFR) and a permeate (MFP); (b) ultrafiltration (UF) of the MEP originating from step (a) over a membrane having a molecular weight cut-off of at most 25 kDa and operating with a volume concentration factor of 1.5-8, resulting in a retentate (UFR) and a permeate fUEP); (c) combining the MFR from step (a) and the UFR from step (b), to obtain a defined casein/whey ratio. Alternatively, the product of step (a) is used as a protein source. Claimed is also a composition comprising 40-50 g casein, 30-40 g lactose and 5-16 g ash per 100 g dry weight.

Abstract: The invention pertains to the use of one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof in the manufacture of a composition for treating, preventing or reducing the risk of occurrence of white matter lesions, white matter hyperintensities (WMH), Leukoaraiosis or periventricular white matter disease in elderly not suffering from a neurodegenerative disorder, preferably non-demented elderly and elderly not suffering from Alzheimer's Disease. It was found that with the compositions according to the invention Nogo-A protein levels could be controlled, particularly suppressed or reduced.

Abstract: The invention concerns nutritional compositions with fucosyllactose for use in stimulation of NK cells. The composition is suitable for infants.

Abstract: The invention relates to prevention of insulin resistance or low-grade chronic inflammation later in life upon ingestion of synbiotics early in life.

Abstract: The invention pertains to the use of a composition in the manufacture of a product or method for therapeutically improving, promoting, restoring or maintaining recognition and/or working memory in a subject suffering from PKU and/or in a subject suffering from or at increased risk of impaired recognition and/or working memory associated with PKU, said composition comprising therapeutic amounts of: (i) at least one ?-3 polyunsaturated fatty acid (LCPUFA) selected from the group consisting of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA); (ii) choline, a choline salt and/or choline ester; and (iii) at least one B vitamin selected from the group consisting of vitamin B6, vitamin B12 and vitamin B9, including functional equivalents thereof, preferably vitamin B6 and/or vitamin B12, and functional equivalents thereof. The invention also pertains to a composition for use in such use or method.

Abstract: The invention pertains to a composition for use in (a) treatment of impaired motor skills in a mammal suffering from Parkinson's Disease; (b) improving the efficacy of levodopa (L-DOPA) in treatment of impaired motor skills in a mammal suffering from Parkinson's Disease; and/or (c) reducing L-DOPA associated side effects, preferably involuntary movements selected from the group consisting of choreiform, dystonic and dyskinetic movements, in the treatment of impaired motor skills in a mammal suffering from Parkinson's Disease, comprising co-administering to the subject L-DOPA and a composition comprising therapeutically effective amounts of: (i) at least one of uridine, cytidine, or salts, phosphates, acyl derivatives or esters thereof; (ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA); (iii) choline, or salts or esters thereof; and (iv) at least one vitamin B selected from vitamins B6, B9 and B12.

Abstract: An infant formula for preventing gastro-esophageal reflux is disclosed comprising whey protein and/or casein, a galactomannan thickener, and a fermented milk-derived product.

Abstract: The invention concerns nutritional compositions with fucosyllactose for use in stimulation of NK cells. The composition is suitable for infants.

Abstract: The present invention relates to infant nutrition, in particular to infant nutrition comprising special lipid globules for improvement of the fatty acid composition in brain membranes.

Abstract: The present invention relates to the field of prebiotics. Provided are uses for compositions comprising synergistically effective amounts of polyfructose and galactooligosaccharides (GOS).